Physician profile
Robert Wright Bedinger
NPI 1700836434
$12,495.69
in general payments reported to CMS, 2019-2025
66 companies · $1,169 in 2025
The $1,169 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,625 · 2020: $1,566 · 2021: $1,951 · 2022: $1,989 · 2023: $2,099 · 2024: $2,097 · 2025: $1,169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,339 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,339.48 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,768.60 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $1,731.82 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,084.28 | 2019-2025 | Repatha, Evenity, Prolia |
| Astrazeneca Pharmaceuticals Lp | $838.75 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $689.95 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $648.82 | 2019-2025 | |
| Lilly USA, LLC | $608.21 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $500.08 | 2019-2025 | Capvaxive, Gardasil 9, Belsomra |
| Novartis Pharmaceuticals Corporation | $481.69 | 2021-2025 | |
| Abbott Laboratories | $469.25 | 2020-2025 | Freestyle Libre 3, Proclaim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $439.06 | 2019-2023 | Jardiance |
| Amarin Pharma, INC. | $356.61 | 2019-2021 | |
| Esperion Therapeutics, INC. | $186.59 | 2020-2025 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $177.49 | 2019-2025 | Trintellix |
| Astellas Pharma US INC | $162.63 | 2019-2021 |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Bedinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.